Biofrontera

Biofrontera AG engages in the research, development, and marketing of dermatological products. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021.

Biofrontera reports preliminary revenue for the month of August 2021

Biofrontera AG's (BFRA) CEO Hermann Lübbert on Q2 2021 Results - Earnings Call Transcript

Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2021.

Biofrontera reports financial results for the six months ended June 30, 2021

Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021.

Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021

Biofrontera has filed to raise $25 million in an IPO. The firm sells licensed treatments for skin conditions due to overexposure to the sun.

Biofrontera Pursues Spin-Out IPO Plan

Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für klinische Spezialpräparate mbH. (Medac), signed an exclusive license and supply agreement for the marketing of both Ameluz® and BF-RhodoLED® in Poland. The agreement has a term of 5 years commencing with the start of sales in Poland.

Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland

Biofrontera Inc. is presently a wholly owned U.S. subsidiary of Biofrontera AG (BFRA).

Biofrontera Inc.: U.S. Subsidiary Of German Dermatology Company Files S-1

Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc.

Biofrontera Inc. seeks IPO in the USA

Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of June 2021.

Biofrontera reports preliminary revenue for the month of June 2021

Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of May 2021.

Biofrontera reports preliminary revenue for the month of May 2021

Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021.

Biofrontera reports Q1 2021 financial results

Leverkusen, Germany, May 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of April 2021.

Biofrontera reports preliminary revenue for the month of April 2021

Leverkusen, Germany, May 03, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its

Biofrontera AG: First quarter conference call to be held on May 12, 2021

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q4 2020 Results - Earnings Call Transcript

Leverkusen, Germany, April 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its consolidated results for the fiscal year ended December 31, 2020. At the same time, the Company provided an overview of current operational and clinical developments.

Biofrontera reports results for the 2020 financial year

Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the first quarter 2021.

Biofrontera announces preliminary revenue for Q1 2021

Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the fiscal year 2020 on Monday, April 12, 2021.

Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results

Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the submission for approval of a new, significantly larger red-light source for photodynamic therapy (PDT) to be used in combination with Ameluz®, the BF-RhodoLED® XL, to the U.S. Food and Drug Administration (FDA).

Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp

Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, announces the closing of the capital increase resolved by the annual general meeting on May 28, 2020.

Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million

Biofrontera AG (NASDAQ: BFRA) priced an underwritten public offering of around 1.3 million ADS at $6.68 per ADS, raising gross proceeds of approximately $8.9 million. The offer price represents a discount of 5% from the last close price of $7.04 on Tuesday.

Biofrontera Raises $8.9M Via Equity Offering

NOT FOR DISTRIBUTION OUTSIDE THE UNITED STATES

Biofrontera AG Announces Pricing of US$8.9 Million Firm Commitment Public Offering of American Depositary Shares

Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a change in the company's Management Board. Effective March 1, 2021, Mr. Ludwig Lutter has been appointed as the new Chief Financial Officer (CFO) of Biofrontera AG. He succeeds Thomas Schaffer and will be responsible for Finance, Administration, Controlling and Human Resources within the company. Thomas Schaffer will be leaving the Company by best mutual consent on February 28, 2021, to pursue new personal commitments outside the Company. This change is part of the succession planning previously announced by the Supervisory Board and the Management Board.

Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021

Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the full year 2020.

Biofrontera announces preliminary revenue figures for the full year 2020

Leverkusen, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the Cologne Higher Regional Court has granted the release of the capital increase resolved by the Annual General Meeting on May 28, 2020.

Cologne Higher Regional Court grants approval of capital increase

Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö, Sweden, today signed an exclusive license and supply agreement for the marketing of both Ameluz® and BF-RhodoLED® in Sweden, Norway, Denmark, Finland and Iceland.

News for Biofrontera Stock (BFRA)